Bank of New York Mellon’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-260,902
| Closed | -$6.24M | – | 4546 |
|
|
2021
Q1 | $6.24M | Sell |
260,902
-9,771
| -4% | -$182K | ﹤0.01% | 2343 |
|
|
2020
Q4 | $3.95M | Buy |
270,673
+1,426
| +0.5% | +$18.9K | ﹤0.01% | 2466 |
|
|
2020
Q3 | $3.82M | Sell |
269,247
-64,375
| -19% | -$984K | ﹤0.01% | 2357 |
|
|
2020
Q2 | $4.91M | Buy |
333,622
+92,363
| +38% | +$938K | ﹤0.01% | 2214 |
|
|
2020
Q1 | $994K | Sell |
241,259
-224
| -0.1% | -$1.05K | ﹤0.01% | 2987 |
|
|
2019
Q4 | $1.16M | Buy |
241,483
+6,157
| +3% | +$34K | ﹤0.01% | 3164 |
|
|
2019
Q3 | $1.43M | Buy |
235,326
+7,883
| +3% | +$49.2K | ﹤0.01% | 2940 |
|
|
2019
Q2 | $1.48M | Sell |
227,443
-11,730
| -5% | -$82.7K | ﹤0.01% | 2987 |
|
|
2019
Q1 | $1.7M | Buy |
239,173
+6,562
| +3% | +$43.2K | ﹤0.01% | 2862 |
|
|
2018
Q4 | $1.13M | Buy |
232,611
+16,279
| +8% | +$84.8K | ﹤0.01% | 3036 |
|
|
2018
Q3 | $1.59M | Sell |
216,332
-1,243
| -0.6% | -$9.12K | ﹤0.01% | 2991 |
|
|
2018
Q2 | $1.39M | Sell |
217,575
-16,774
| -7% | -$111K | ﹤0.01% | 3058 |
|
|
2018
Q1 | $1.27M | Sell |
234,349
-7,995
| -3% | -$39.7K | ﹤0.01% | 3074 |
|
|
2017
Q4 | $1.01M | Sell |
242,344
-4,616
| -2% | -$27.8K | ﹤0.01% | 3243 |
|
|
2017
Q3 | $2.38M | Buy |
246,960
+23,797
| +11% | +$247K | ﹤0.01% | 2739 |
|
|
2017
Q2 | $2.64M | Buy |
223,163
+18,235
| +9% | +$233K | ﹤0.01% | 2683 |
|
|
2017
Q1 | $2.63M | Buy |
204,928
+6,482
| +3% | +$78K | ﹤0.01% | 2679 |
|
|
2016
Q4 | $2.43M | Buy |
198,446
+22,815
| +13% | +$271K | ﹤0.01% | 2736 |
|
|
2016
Q3 | $2.07M | Sell |
175,631
-10,026
| -5% | -$96.8K | ﹤0.01% | 2732 |
|
|
2016
Q2 | $1.61M | Buy |
185,657
+3,999
| +2% | +$27.4K | ﹤0.01% | 2845 |
|
|
2016
Q1 | $957K | Sell |
181,658
-7,138
| -4% | -$39.7K | ﹤0.01% | 3087 |
|
|
2015
Q4 | $1.47M | Buy |
188,796
+14,415
| +8% | +$111K | ﹤0.01% | 2898 |
|
|
2015
Q3 | $1.37M | Sell |
174,381
-40,283
| -19% | -$373K | ﹤0.01% | 2989 |
|
|
2015
Q2 | $1.95M | Buy |
214,664
+15,138
| +8% | +$153K | ﹤0.01% | 2929 |
|
|
2015
Q1 | $2.59M | Sell |
199,526
-106
| -0.1% | -$1.39K | ﹤0.01% | 2685 |
|
|
2014
Q4 | $2.72M | Buy |
199,632
+5,693
| +3% | +$63.7K | ﹤0.01% | 2650 |
|
|
2014
Q3 | $1.74M | Buy |
193,939
+18,305
| +10% | +$197K | ﹤0.01% | 2973 |
|
|
2014
Q2 | $2.38M | Sell |
175,634
-2,013
| -1% | -$21K | ﹤0.01% | 2799 |
|
|
2014
Q1 | $1.77M | Sell |
177,647
-28,126
| -14% | -$349K | ﹤0.01% | 2950 |
|
|
2013
Q4 | $2.73M | Buy |
205,773
+62,204
| +43% | +$755K | ﹤0.01% | 2684 |
|
|
2013
Q3 | $1.74M | Buy |
143,569
+26,636
| +23% | +$286K | ﹤0.01% | 2918 |
|
|
2013
Q2 | $1.21M | Buy |
+116,933
| New | +$1.61M | ﹤0.01% | 3080 |
|
Bank of New York Mellon's GNMK Position: Q2 2021 in Review
Bank of New York Mellon sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 260,902 shares — an estimated $6.24M sold.
Bank of New York Mellon first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $6.24M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Bank of New York Mellon reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Bank of New York Mellon sold 260,902 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $6.24M.
- Bank of New York Mellon first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Bank of New York Mellon's GenMark Diagnostics, Inc position peaked at $6.24M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.